Information checked: November 7, 2026, 12:10 p.m. Sydney time (Australian Eastern Daylight Time, AEDT, UTC+11:00; 01:10 UTC). Australia has approved a daily tablet version of Novo Nordisk’s Wegovy, but there is still no confirmed Australian retail price for the Wegovy pill. The Therapeutic Goods Administration (TGA) registered four oral semaglutide strengths on November 3, 2026. Approval is a major step for people considering a prescription weight-management treatment without weekly injections, but it does not establish what a pharmacy will charge.
The other crucial distinction is availability. Diabetes Australia said on November 6 that further product and packaging work was needed and that the Australian launch date and price were still to be confirmed. Australians should therefore treat any specific monthly tablet price circulating online as unverified unless the manufacturer or a dispensing pharmacy provides a current Australian quote. Diabetes Australia’s November 6 statement makes this distinction explicit.
The short answer is that its price remains unknown. The TGA’s Australian Register of Therapeutic Goods (ARTG) records the oral medication and its sponsor, Novo Nordisk Pharmaceuticals Pty Ltd, but an ARTG entry is not a pharmacy price list. As of November 7, neither a standard Australian pack price nor a confirmed price for a 28-day or 30-day supply could be established from the official sources checked.
That matters because a headline about an overseas launch price can easily create the wrong expectation. Novo Nordisk advertised a US$149 per month starting-dose self-pay offer in the United States when it launched the pill there in January 2026. That is a U.S. offer in U.S. dollars for a specific dose and program, not an Australian list price, not a general price for every strength, and not a promise of availability to Australian buyers. See Novo Nordisk’s U.S. launch announcement.
Australian private prices can depend on the formulation, the prescribed strength, pack size, pharmacy charges, supply arrangements, and any manufacturer pricing programs ultimately introduced. These factors are relevant to the final bill, but none provides a reliable numerical estimate for the Australian pill today. Converting U.S. dollars to Australian dollars would be especially misleading because it would ignore the Australian supply chain and local pricing decisions.
The TGA register entry for Wegovy 25 mg tablets lists November 3, 2026, as the registration date, identifies semaglutide as the active ingredient, and names Novo Nordisk Pharmaceuticals Pty Ltd as sponsor. Separate official entries cover 1.5 mg, 4 mg, and 9 mg. These are four tablet strengths, not four price tiers. A patient’s dose must be determined by the prescriber rather than by comparing milligrams with the injectable product.
| Question | Confirmed position on November 7, 2026 |
|---|---|
| Is oral Wegovy approved in Australia? | Yes. Four tablet strengths were registered on November 3. |
| Is an Australian retail price public? | No verified price was found in the official information checked. |
| Can patients assume it is in pharmacies now? | No. Australian availability has not been confirmed. |
| Is a PBS price for the weight-loss pill confirmed? | No confirmed oral Wegovy weight-management listing was established. |
| Is the U.S. starting-dose offer the Australian price? | No. It is a separate U.S. commercial offer. |
The tablet is a once-daily formulation of semaglutide, a medicine in the glucagon-like peptide-1 (GLP-1) receptor agonist class. The Australian approval has been welcomed by Diabetes Australia as an additional option for people who are hesitant about injections, while the organization stresses that affordability and access remain separate questions. A prescription and clinical assessment will still be required; the approval is not a general over-the-counter sale authorization.
There is not enough Australian pricing evidence to say. Oral Wegovy and injectable Wegovy contain the same active ingredient, but they are different formulations with different dosing and administration. A daily tablet may be more convenient for some people, while others may prefer weekly injections. Convenience does not guarantee a lower price, and the higher milligram number on a tablet does not mean its cost or clinical effect can be calculated from an injection’s dose.
There is an established private-pay market for injectable weight-management medicines. In an August 10, 2026 Australian government interview, Health Minister Mark Butler described possible private-market treatment costs reaching A$5,000–A$6,000 a year for people using these medicines. That was a broad discussion of GLP-1 access and affordability, not a price quotation for oral Wegovy. It illustrates why the future Australian pill price will be important but cannot be used as a forecast of the tablet’s monthly charge.
For a meaningful comparison after launch, a consumer should ask a pharmacist for the full cost of the prescribed formulation and quantity, check whether the quote is private or subsidized, and include any consultation or delivery fees separately. A first-month promotional amount should not be mistaken for the ongoing cost of a long-term prescription.
TGA approval and Pharmaceutical Benefits Scheme (PBS) subsidy are different decisions. The TGA assesses medicines for registration; PBS coverage depends on a separate funding and listing process. As the Australian Government’s medicines-cost guidance explains, medicines not covered by the PBS or another relevant program generally must be paid for at full price, and different pharmacies may charge different amounts.
Australia has separately considered targeted PBS access for Wegovy in certain high-risk patient groups. The Health Minister said in August 2026 that discussions on a price for a restricted Wegovy weight-management listing had not reached agreement. That policy discussion should not be interpreted as an active PBS subsidy for the newly registered tablet. Novo Nordisk’s Australian healthcare-professional Wegovy information page also identifies Wegovy as not PBS listed, although readers should confirm the exact formulation and current status when tablets become available.
The much-publicized 2026 PBS patient co-payment cap only helps when a medicine and the patient’s specific use qualify for subsidy. A listed price for another semaglutide brand or a diabetes indication does not automatically transfer to oral Wegovy for weight management.
No firm nationwide Australian pharmacy release date has been verified. Diabetes Australia stated on November 6 that additional work on the product and packaging remained before supply, with availability and pricing still to be confirmed. A plan to launch later in 2026 is therefore a possible timetable, not a guaranteed date or evidence that stock is ready to dispense.
Before purchasing, check three things independently: whether the tablet has actually launched at Australian pharmacies; the current price for the prescribed strength and pack size; and whether that prescription qualifies for any subsidy. The best evidence will be a direct manufacturer update, a TGA or PBS notice, and a real quote from a licensed Australian pharmacy.
Not exactly. All three names involve semaglutide, but brand, approved purpose, strength, and formulation matter. Wegovy has a weight-management indication; Ozempic is used in the treatment of type 2 diabetes under its approved indications. Rybelsus is another semaglutide tablet registered in Australia for adults with insufficiently controlled type 2 diabetes. The TGA decision summary for Rybelsus confirms that established diabetes indication.
Thus, oral Wegovy is an important new weight-management tablet, but it is not accurate to say Australia has never registered any oral GLP-1 medicine before. Nor should patients substitute Rybelsus, Ozempic, injectable Wegovy, or the newly registered Wegovy tablet without a clinician’s guidance. Different formulations are not milligram-for-milligram interchangeable.
Anyone considering treatment should speak with a GP, specialist, or pharmacist about eligibility, other conditions, current medicines, precautions, and expected follow-up. Oral semaglutide has specific administration instructions; the final Australian consumer medicine information and the prescriber’s advice should take priority over dosing tips copied from U.S. advertisements or social-media posts.
Patients should also be wary of websites claiming to sell the newly approved pill before verified Australian pharmacy supply begins. The Australian Novo Nordisk guidance on compounded medicines warns that unapproved compounded semaglutide products do not carry the same quality, safety, and effectiveness assurances as TGA-registered products. A lower online offer is not proof of a genuine Wegovy tablet.
The next useful milestones are a confirmed commercial supply announcement, a published Australian pharmacy price for each supplied pack, and any formal PBS decision that specifically covers the oral formulation or defined patient groups. The order and timing of those developments are not guaranteed. If the product launches privately before any subsidy, eligible patients may initially face the full pharmacy charge; if a future PBS listing is approved, actual patient costs would depend on that listing’s rules.
Bottom line: Australia’s November 3 registration is real, but it is not a price announcement. Until a credible Australian source publishes a retail price, the answer to “How much does the Wegovy pill cost in Australia?” remains not yet confirmed.
No confirmed Australian monthly price was available from the official sources checked on November 7, 2026. U.S. offers and local injection prices are not valid substitutes for an Australian tablet quote.
Its four strengths are registered with the TGA, but commercial pharmacy availability had not been confirmed at the time of checking. Ask a licensed pharmacy after a verified Australian launch announcement.
Not automatically. TGA registration is distinct from PBS funding, and no confirmed PBS listing for oral Wegovy for weight management was established in the sources checked. Any future subsidy would require a separate decision and eligibility rules.
Australia approved Wegovy tablets on November 3, 2026, but the local price is not confirmed. Check pharmacy availability, PBS status, and U.S. price comparisons.
Usman Khawaja’s Sabr claims Australia’s sandpaper use began before Cape Town and was widely known. Here’s how his account compares with the 2018 findings.
Prince William and Prince Harry both support the Diana Award. Learn what the charity does, whom it honors and how to nominate a young changemaker.
Nelson Asofa-Solomona knocked out Paul Gallen in the first round in Sydney. Here are the result, fight details and what comes next.
Who was Judi Dench’s husband? Meet actor Michael Williams, explore their nearly 30-year marriage, family, shared roles, and her latest Friday-rose story.
Compare Coles and Woolworths roast chicken on price, portions, ingredients and food safety, plus details of Woolworths’ upcoming Mad Mex flavor.
DWP says most Winter Fuel Payments arrive in November or December 2026. Check eligibility, amounts, letters, and the January 27, 2027 follow-up date.
Find your PlayStation Plus perks in the UK, check your membership tier, claim monthly games, and understand which benefits need Extra or Premium.
Learn how to identify UK speed limits using signs, streetlights, road types and vehicle rules, including Wales’s 20 mph default.
Mary Earps and partner Kitty Forrest have welcomed a baby boy. Here is what the former England goalkeeper has publicly shared about their relationship.
